GSK 2879552

Drug Profile

GSK 2879552

Alternative Names: GSK-2879552

Latest Information Update: 18 Aug 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator GlaxoSmithKline
  • Class Antineoplastics
  • Mechanism of Action Co-repressor protein inhibitors; Lysine specific demethylase 1 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I/II Myelodysplastic syndromes
  • Phase I Acute myeloid leukaemia; Small cell lung cancer

Most Recent Events

  • 01 Aug 2017 GlaxoSmithKline terminates a phase I trial for Small cell lung cancer (Second-line therapy or greater) in USA, France and Spain (NCT02034123)
  • 31 Jul 2017 Phase-I/II clinical trials in Myelodysplastic syndromes in USA (PO) (NCT02929498)
  • 15 Dec 2016 Biomarkers information updated
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top